The abstract is read at the publisher; the summary is JClub's.
Intratumoral MEDI1191 plus intravenous durvalumab showed no dose-limiting toxicities in 61 patients with advanced solid tumors, with an objective response rate of 9.8%.
- Why it matters: The study addresses the need for safer ways to boost antitumor T-cell activity in heavily pretreated advanced cancers, including those progressing after PD-(L)1 therapy.
- What they did: In a first-in-human, open-label phase I dose-escalation (NCT03946800), patients received intratumoral MEDI1191 with durvalumab sequentially or concurrently, targeting noninjected RECIST v1.1 lesions.
- The result: Responses were observed across injected, local noninjected, and distant lesions, with duration of response ranging from 2.7 to 22.3 months, and 3 of 39 prior anti-PD-(L)1 patients achieving PRs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.